Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

[1]  G. Hindricks,et al.  Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  David O. Martin,et al.  Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation , 2013, Circulation. Arrhythmia and electrophysiology.

[3]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[4]  S. Kusachi,et al.  Usefulness of Dabigatran Etexilate as Periprocedural Anticoagulation Therapy for Atrial Fibrillation Ablation , 2013, Clinical Drug Investigation.

[5]  B. Knight,et al.  Optimal Strategies Including Use of Newer Anticoagulants for Prevention of Stroke and Bleeding Complications Before, During, and After Catheter Ablation of Atrial Fibrillation and Atrial Flutter , 2013, Current Treatment Options in Cardiovascular Medicine.

[6]  F. Morady,et al.  Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. , 2013, Heart rhythm.

[7]  D. Garcia,et al.  The Novel Oral Anticoagulants , 2013, Seminars in Thrombosis & Hemostasis.

[8]  T. Murohara,et al.  A Randomized Controlled Trial of Dabigatran versus Warfarin for Periablation Anticoagulation in Patients Undergoing Ablation of Atrial Fibrillation , 2013, Pacing and clinical electrophysiology : PACE.

[9]  A. Natale,et al.  How to ablate long-standing persistent atrial fibrillation? , 2012, Current opinion in cardiology.

[10]  S. Oshima,et al.  Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[11]  R. Winkle,et al.  Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[12]  A. Pillai,et al.  Rivaroxaban and its Effect on International Normalised Ratio-A Prospective Study of 28 Hip and Knee Arthroplasty Patients , 2012 .

[13]  David Keane,et al.  2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  J. Burkhardt,et al.  Ablation of Atrial Fibrillation Under Therapeutic Warfarin Reduces Periprocedural Complications: Evidence From a Meta-Analysis , 2012, Circulation. Arrhythmia and electrophysiology.

[15]  R. Winkle,et al.  The Use of Dabigatran Immediately After Atrial Fibrillation Ablation , 2012, Journal of cardiovascular electrophysiology.

[16]  P. Kirchhof,et al.  Bleeding risk assessment and management in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[17]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[18]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[19]  K. Ylitalo,et al.  Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[20]  John Camm,et al.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  A. Natale,et al.  Atrial Fibrillation Ablation without Interruption of Anticoagulation , 2011, Cardiology research and practice.

[22]  G. Hankey,et al.  Dabigatran Etexilate: A New Oral Thrombin Inhibitor , 2011, Circulation.

[23]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[24]  D. Mehta,et al.  Thromboembolic Risk and Anticoagulation Strategies in Patients Undergoing Catheter Ablation for Atrial Fibrillation , 2011, Current cardiology reports.

[25]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[26]  E. Heist,et al.  Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation , 2011, Journal of Interventional Cardiac Electrophysiology.

[27]  Carlo Boffano,et al.  Radiofrequency Catheter Ablation of Atrial Fibrillation: A Cause of Silent Thromboembolism?: Magnetic Resonance Imaging Assessment of Cerebral Thromboembolism in Patients Undergoing Ablation of Atrial Fibrillation , 2010, Circulation.

[28]  E. Hylek,et al.  New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs , 2010, Thrombosis and Haemostasis.

[29]  Stacy A. Johnson,et al.  Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. , 2010, Thrombosis research.

[30]  Sanghamitra Mohanty,et al.  Left Atrial Appendage: An Underrecognized Trigger Site of Atrial Fibrillation , 2010, Circulation.

[31]  Dhanunjaya R. Lakkireddy,et al.  Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The Impact of Periprocedural Therapeutic International Normalized Ratio , 2010, Circulation.

[32]  S. Johnston,et al.  Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States , 2010, Clinical cardiology.

[33]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[34]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[35]  Thorsten Lewalter,et al.  Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[36]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[37]  David O. Martin,et al.  Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. , 2009, Heart rhythm.

[38]  Douglas Packer,et al.  Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[39]  Yuping Xiao,et al.  Femoral vascular complications following catheter ablation of atrial fibrillation , 2009, Journal of Interventional Cardiac Electrophysiology.

[40]  T. Kuwahara,et al.  Complications in the catheter ablation of atrial fibrillation: incidence and management. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[41]  A. Waldo.  Complications of Catheter Ablation for Atrial Fibrillation: Incidence and Predictors , 2009 .

[42]  Bengt I Eriksson,et al.  Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement , 2008, Thrombosis and Haemostasis.

[43]  W. Mueck,et al.  Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects , 2008 .

[44]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[45]  J. Sra.  Atrial fibrillation ablation complications , 2008, Journal of Interventional Cardiac Electrophysiology.

[46]  David O. Martin,et al.  Atrial Fibrillation Ablation in Patients With Therapeutic International Normalized Ratio: Comparison of Strategies of Anticoagulation Management in the Periprocedural Period , 2007, Circulation.

[47]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[48]  F. Marchlinski,et al.  How to recognize, manage, and prevent complications during atrial fibrillation ablation. , 2007, Heart rhythm.

[49]  A. Natale,et al.  How to do circular mapping catheter-guided pulmonary vein antrum isolation: the Cleveland Clinic approach. , 2006, Heart rhythm.

[50]  Michael Becka,et al.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.

[51]  Atul Verma,et al.  Pulmonary Vein Antrum Isolation: , 2004, Journal of cardiovascular electrophysiology.

[52]  David O. Martin,et al.  Impact of Age on the Outcome of Pulmonary Vein Isolation for Atrial Fibrillation Using Circular Mapping Technique and Cooled‐Tip Ablation Catheter: , 2004, Journal of cardiovascular electrophysiology.